(tore-em-i-feen) ,


(trade name)


Therapeutic: antineoplastics
Pharmacologic: antiestrogens
Pregnancy Category: D


Management of metastatic breast cancer in postmenopausal women with estrogen receptor–positive or unknown tumors.


Exerts antiestrogenic effects by competing for estrogen-binding sites found in breast cancers.

Therapeutic effects

Regression of breast cancer.


Absorption: Well absorbed following oral administration.
Distribution: Widely distributed; 99% bound to plasma proteins.
Protein Binding: 99.5%.
Metabolism and Excretion: Extensively metabolized; undergoes enterohepatic circulation.
Half-life: 5 days.

Time/action profile (blood levels)

POunknown3 hr4–6 wk†
†Steady-state blood levels occur after 4–6 wk


Contraindicated in: Hypersensitivity; Obstetric / Lactation: Pregnancy or lactation; History of thromboembolic disease; Congenital or acquired QT prolongation, hypokalemia, or hypomagnesemia; Concurrent use of QT-interval prolonging medications or strong CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole).
Use Cautiously in: Bone metastases (↑ risk of hypercalcemia); Heart failure; Hepatic impairment; Pre-existing endometrial hyperplasia (long-term treatment should be avoided).

Adverse Reactions/Side Effects

Central nervous system

  • depression
  • dizziness
  • headache
  • lethargy

Ear, Eye, Nose, Throat

  • blurred vision
  • cataracts
  • corneal keratopathy
  • dry eyes
  • glaucoma


  • HF (life-threatening)
  • MI (life-threatening)
  • pulmonary embolism (life-threatening)
  • torsade de pointes (life-threatening)
  • angina
  • arrhythmias
  • edema
  • QTc interval prolongation
  • thrombophlebitis


  • nausea (most frequent)
  • elevated liver enzymes
  • vomiting


  • vaginal discharge (most frequent)
  • vaginal bleeding


  • sweating (most frequent)

Fluid and Electrolyte

  • hypercalcemia


  • anemia


  • hot flashes (most frequent)
  • tumor flare


Drug-Drug interaction

QT-prolonging drugs may ↑ the risk of torsade de pointes; avoid concurrent use.Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole may ↑ levels; avoid concurrent use.Strong CYP3A4 inducers, including dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, and phenobarbital may ↓ levels.Concurrent use of agents that ↓ urinary excretion of calcium (thiazidediuretics) may ↑ the risk of hypercalcemia.May ↑ the effects of warfarin and phenytoin.St. John's wort may ↓ levels.


Oral (Adults) 60 mg once daily.


Tablets: 60 mg

Nursing implications

Nursing assessment

  • Assess for an increase in bone or tumor pain. May be indicative of tumor flare and hypercalcemia if during early therapy. Confer with health care professional regarding analgesics. This transient pain usually resolves despite continued therapy.
  • Gynecologic examinations should be done regularly; may cause variations in Papanicolaou and vaginal smears.
  • Lab Test Considerations: Monitor CBC, platelets, and calcium levels prior to and periodically throughout therapy. May cause transient hypercalcemia in patients with metastases to bone. An estrogen receptor assay should be assessed prior to initiation of therapy.
    • Monitor hepatic function tests periodically during therapy. May cause elevated serum AST, alkaline phosphatase, and bilirubin concentrations.

Potential Nursing Diagnoses

Acute pain (Adverse Reactions)


  • Hypokalemia and hypomagnesemia should be corrected prior to starting therapy.
  • Oral: Administer once daily.

Patient/Family Teaching

  • Instruct patient to take medication exactly as directed. If a dose is missed, it should be omitted.
  • Advise patient to report bone pain to health care professional promptly. This pain may be severe. Inform patient that this may be an indication of the drug’s effectiveness and will resolve over time. Analgesics should be ordered to control pain.
  • Advise patient that medication may cause hot flashes. Notify health care professional if these become bothersome.
  • Instruct patient to notify health care professional promptly if pain or swelling of legs, shortness of breath, weakness, sleepiness, confusion, nausea, vomiting, dizziness, headache, loss of appetite, or blurred vision occurs. Patient should also report menstrual irregularities, vaginal bleeding, pelvic pain or pressure.
  • This medication may induce ovulation and may have teratogenic properties. Advise patient to use a nonhormonal method of contraception during and for 1 mo after the course of therapy.

Evaluation/Desired Outcomes

  • Decrease in the size or spread of breast cancer.
Drug Guide, © 2015 Farlex and Partners


Toremifene citrate Oncology An antiestrogen used for postmenopausal Pts with estrogen-receptor-positive or receptor-unknown metastatic breast CA. See Breast cancer.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


A brand name for TOREMIFENE.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
Mentioned in ?
References in periodicals archive ?
The global breast cancer therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes - brand name (chemical name) such as antimetabolites - Gemzar (gemcitabine), aromatase inhibitors - Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors - Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors - Fareston, Faslodex, Zoladex; and Mitotic inhibitors - Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% - 2016 to 2020).
M2 EQUITYBITES-October 2, 2012-GTx Inc reports divestiture of Fareston along with product inventory under Asset Purchase Agreement(C)2012 M2 COMMUNICATIONS http://www.m2.com
Biopharmaceutical company GTx Inc (NasdaqGM:GTXI) reported on Monday the completion of the sale of its rights and related assets in the metastatic breast cancer product, Fareston, for total cash consideration of USD21.7m to ProStrakan Group plc (ProStrakan).
The accord grants Eisai exclusive rights to sell Orion's breast cancer drug Fareston and its drug to treat Parkinson's disease, Eldepryl, in China.
Fareston is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor positive or unknown tumors and is commonly used as an adjuvant therapy in postmenopausal breast cancer.
will establish a new presence in China the area of women's oncology by marketing Fareston, and with the addition of Eldepryl, will further enhance its lineup of neurology products, which currently includes the anti-Alzheimer's agent Aricept(R) and the peripheral neuropathy treatment Methycobal(R), as it seeks to make further contributions to address the diversified needs of and increase the benefits provided to breast cancer and Parkinson's disease patients in China.
Eisai's unit Eisai China Inc will distribute the breast cancer drug Fareston (toremifene citrate) and Eldepryl (selegiline hydrochloride), for treatment of Parkinson's disease.
The company sells the drug, a selective estrogen receptor modulator, under the brand name Fareston for breast cancer and is developing it for prostate cancer under the name Acapodene.
Toremifene (Fareston) has properties and side effects similar to tamoxifen but does not seem to increase the risk of endometrial cancer.
Recently a new drug called Fareston (toremifene citrate) has also been found to fight breast cancer successfully.
In the first 6 months of 1997, the following new drugs were approved by the FDA: Agrylin, Alesse, Anzemet, Carbatrol, Fareston, Flomax, Galzin, Idamycin, Migranal, Posicor, Prelay, Prevacid, Pytest, Requip, Resulin, Serlect, Skelid, Tasmar, Uniretic, Urso, Vicoprofen, Viracept, Zyban.
The arrangement with GTx means the termination of the US marketing licence for 'Fareston' held by Shire Pharmaceuticals Group plc, and the transfer of the US marketing authorisation to GTx, Orion added.